GRAIL Stock: IPO History and Valuation

Biotech / Life Sciences
By UpMarket Research  |  Last updated: July 2026
Founded 2016 HQ Menlo Park, US

GRAIL is a healthcare company focused on early cancer detection using next-generation sequencing, clinical studies, machine learning, software, and automation. It develops blood-based tests intended to identify cancers before symptoms appear, aiming to improve treatment outcomes.

UpMarket does not offer GRAIL shares. This page covers GRAIL's history before it went public.

Latest Price
Previous Price
Series D Apr 2020

How to Review GRAIL's Pre-IPO History on UpMarket

GRAIL became a public company on June 25, 2024 and trades on Nasdaq as GRAL. UpMarket does not offer GRAIL shares. This page covers GRAIL's valuation and funding history before it went public.

Step 01

Check the listing details

GRAIL listed on Nasdaq under the ticker GRAL on June 25, 2024.

Step 02

Review the valuation history

See how GRAIL's private-market valuation changed across funding rounds before it went public.

Step 03

Review funding and revenue data

See reported funding rounds and revenue figures on this page, with their sources.

Step 04

Explore private companies

Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.

Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.

${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.

Valuation Growth Over Time

Post-money valuation by round
Previous rounds Most recent
DateRoundPPS (split-adj.)Valuation
Jun 2020 Series D
Apr 2020 Series D
Mar 2018 Series C
May 2017 Series B
Jan 2016 Series A

GRAIL Revenue and Growth

Annual revenue

Why Investors Are Watching GRAIL

Growth Signal

GRAIL raises $325M to extend runway and fund growth

GRAIL announced a $325.0 million private placement with new and existing institutional investors, including Deep Track Capital and Farallon Capital. The company said its cash, cash equivalents and investments, including net proceeds, are expected to provide sufficient funding for its plans.

Product Milestone

GRAIL builds blood tests for earliest-stage cancer detection

Dealroom describes GRAIL as developing blood tests for early cancer detection using high-intensity sequencing, population-scale clinical trials, and computer science and data science. The company’s core product focus is identifying cancer at its earliest stages to improve treatment outcomes.

Market Opportunity

Multi-cancer screening targets a large unmet oncology market

GRAIL’s approach targets early cancer detection across multiple cancer types, a market framed around improving outcomes by finding disease before symptoms appear. The company’s recent financing suggests investor belief in continued demand for large-scale screening and diagnostics.

Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.

Browse the directory →

GRAIL Leadership Team

Bob Ragusa
CEO
Joshua Ofman
President
Sir Harpal Kumar
President

UpMarket Investment Curation Process

  • Full diligence on every offering

    UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.

  • Strategy, fees & legal reviewed in full

    We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.

  • Disciplined managers only

    We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.

  • Built around your objectives

    Our goal is to empower you to build a portfolio that best meets your individual investment objectives.

Ready to access institutional-grade private market investments? Unlock private markets

GRAIL Stock FAQ

Yes. GRAIL became a public company on June 25, 2024 and trades on Nasdaq under the ticker GRAL. UpMarket does not offer GRAIL shares.

GRAIL's share price is set on the public market under the ticker GRAL. The prices shown on this page are historical private-market prices from before it went public.

No. GRAIL is now a public company and UpMarket does not offer its shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.

GRAIL is now publicly traded, so its shares can be bought and sold on Nasdaq and their price can change significantly. Review GRAIL's public filings and consult a financial advisor before investing. UpMarket does not offer GRAIL shares.

In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.

GRAIL became a public company on June 25, 2024, so shares held before the listing can generally be sold on the public market once any lock-up period ends. The exact terms depend on how the shares are held, for example directly or through a fund.

UpMarket does not offer GRAIL shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.

GRAIL's valuation is now set by its public share price on Nasdaq. The figures on this page show its valuation history before it went public.

GRAIL generated $147.2M in 2025 revenue and focuses on early cancer detection through next-generation sequencing, clinical studies, machine learning, software, and automation, while its $325M capital raise extends runway and funds growth. GRAIL is now a public company, and UpMarket does not offer its shares.

Explore pre-IPO companies Register